iBio’s patented lichenase booster molecule (LickM) is a modified thermostable variant of the lichenase protein from the thermophilic bacterium Clostridium thermocellum. LicKM may be effective in addressing issues with subunit vaccines which have a track record in protecting humans against deadly diseases but are often insufficiently stable and typically require the use of a strong adjuvant to boost their immunogenicity.
Studies have shown that iBio’s LicKM functions both as a carrier of immunogenic epitopes for presentation to antigen-presenting cells during vaccination and as an adjuvant enhancing immunity. LicKM fusion proteins have been shown to strengthen the initial quantitative immune response to the antigen and to increase the duration of the immune response compared with the antigen alone.
iBio is currently incorporating LicKM in its COVID-19 vaccine candidate IBIO-201. Fusing the SARS-CoV-2 spike protein antigens with iBio’s LicKM technology may be advantageous in achieving a robust and prolonged immune response against COVID-19, potentially reducing the challenges associated with adjuvants and stability associated with subunit vaccines.